Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

Autor: Carolyn M. Setze, James C. Stolzenbach, Maureen T. Kelly, Kamlesh Thakker, Kenneth Cusi, Michael H. Davidson, Darryl J. Sleep, Peter B. Jones
Rok vydání: 2010
Předmět:
Male
Simvastatin
medicine.medical_specialty
Statin
medicine.drug_class
Atorvastatin
Population
Type 2 diabetes
Gastroenterology
Double-Blind Method
Fenofibrate
Internal medicine
medicine
Humans
Pyrroles
Pharmacology (medical)
Rosuvastatin
Rosuvastatin Calcium
education
Aged
Dyslipidemias
Hypolipidemic Agents
Randomized Controlled Trials as Topic
Sulfonamides
education.field_of_study
Dose-Response Relationship
Drug
business.industry
nutritional and metabolic diseases
General Medicine
Middle Aged
medicine.disease
Fluorobenzenes
Pyrimidines
Endocrinology
Clinical Trials
Phase III as Topic
Diabetes Mellitus
Type 2
Heptanoic Acids
Drug Therapy
Combination
Female
lipids (amino acids
peptides
and proteins)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
Dyslipidemia
medicine.drug
Zdroj: American Journal Cardiovascular Drugs. 10:73-84
ISSN: 1175-3277
DOI: 10.2165/10061630-000000000-00000
Popis: Monotherapy with lipid-modifying medication is frequently insufficient to normalize lipid abnormalities in patients with mixed dyslipidemia and type 2 diabetes mellitus.To evaluate the efficacy and safety of fenofibric acid + statin combination therapy in this population.A pooled, subgroup analysis of three randomized, controlled, double-blind, 12-week trials.Multiple clinical research facilities in the US and Canada.Patients with mixed dyslipidemia and type 2 diabetes (n = 586).Fenofibric acid (Trilipix) 135 mg monotherapy; low-, moderate-, or high-dose statin monotherapy (rosuvastatin [Crestor] 10, 20, or 40 mg; simvastatin [Zocor] 20, 40, or 80 mg; or atorvastatin [Lipitor] 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin.Mean percentage changes in lipid parameters, percentages of patients achieving optimal serum lipid/apolipoprotein levels, and incidence of adverse events.Fenofibric acid + low-dose statin resulted in significantly (p0.001) greater mean percentage changes in high-density lipoprotein cholesterol (HDL-C) [16.8%] and triglycerides (-43.9%) than low-dose statin monotherapy (4.7% and -18.1%, respectively) and significantly (p0.001) greater reductions in low-density lipoprotein cholesterol (LDL-C) [-34.0%] than fenofibric acid monotherapy (-5.3%). Similarly, fenofibric acid + moderate-dose statin resulted in significantly (por = 0.011) greater mean percentage changes in HDL-C (16.3%) and triglycerides (-43.4%) than moderate-dose statin monotherapy (8.7% and -24.2%, respectively) and significantly (p0.001) greater reductions in LDL-C (-32.6%) than fenofibric acid monotherapy (-5.3%). Compared with low- or moderate-dose statin, fenofibric acid + low- or moderate-dose statin resulted in over 5-fold higher percentages of patients achieving optimal levels of LDL-C, non-HDL-C, apolipoprotein B, HDL-C, and triglycerides simultaneously. Incidence of adverse events was generally similar among treatments.Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy. [Clinical trials are registered at www.clinicaltrials.gov: NCT00300482, NCT00300456, and NCT00300469].
Databáze: OpenAIRE
Externí odkaz: